OS Therapies Incorporated
OSTX
$2.00
$0.189.89%
AMEX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 70.80% | 220.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.70% | 212.57% | |||
| Operating Income | -21.70% | -212.57% | |||
| Income Before Tax | -4.03% | -84.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.03% | -84.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.03% | -84.60% | |||
| EBIT | -21.70% | -212.57% | |||
| EBITDA | -21.65% | -212.85% | |||
| EPS Basic | -26.09% | 30.42% | |||
| Normalized Basic EPS | 23.98% | 30.46% | |||
| EPS Diluted | -26.09% | 30.42% | |||
| Normalized Diluted EPS | 23.98% | 30.46% | |||
| Average Basic Shares Outstanding | 36.87% | 165.36% | |||
| Average Diluted Shares Outstanding | 36.87% | 165.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||